KERENDIA (finerenone) is now PBS listed, with the drug used to delay the progressive decline of kidney function in adults with chronic kidney disease associated with type 2 diabetes (with albuminuria or protein is found in the urine).
It is used in addition to standard medicines for the condition.
Bayer's Kerendia works to block hormones (such as aldosterone and cortisol) from attaching to their receptors (known as mineralocorticoid receptors) in the kidney and blood vessels.
Blocking the over-activity of these receptors may prevent the inflammation and scarring that cause kidney disease to progress.
Kerendia can cause side-effects with the most frequent adverse events being high potassium levels, low sodium levels, and low blood pressure.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jul 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jul 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
